Clinicians can help their patients tap into personal resilience, and such characteristics as grit, gratitude and grace, to manage their chronic pain, says Afton L. Hassett, PsyD.
Search results for: cardiovascular disease
Tips for Balancing Medication Treatment & Risk in Elderly Patients
ACR CONVERGENCE 2020—With the inevitable decline in organ function that comes with age, and the likelihood that older patients (i.e., generally defined as older than 60 or 70, depending on the study) are on more than one medication due to multiple comorbidities, therapeutic drug treatment for older patients requires persistent vigilance and know-how, two experts…
Case Study: Cerebral Toxoplasmosis in a Newly Diagnosed Lupus Patient
The occurrence of opportunistic infections is an established complication in patients diagnosed with systemic lupus erythematosus (SLE). The foremost challenge in such circumstances is differentiating between an exacerbation or progression of SLE, and the effects of the infection itself.1 Toxoplasma gondii is a ubiquitous parasite that often causes an asymptomatic infection in healthy, immunocompetent adults….
Upadacitnib for RA: Researchers Compared Upadacitinib with Placebo & Adalimumab in Patients with RA & an Inadequate Response to Methotrexate
In phase 3 clinical trial, upadacitnib proved superior to placebo and adalimumab in improving the signs and symptoms of RA in patients on stable background methotrexate.
The History of ACE Inhibitors in Scleroderma Renal Crisis
Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…
The 2020 ACR Review Course: Key Issues Rheumatologists Face
The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.
Tofacitinib Promising for Adults with AS
According to a recent phase 3 study, tofacitinib may be a safe and effective treatment for adult patients with ankylosing spondylitis (AS).
Upadacitinib Safety Similar to Other Jakinibs for RA
(Reuters Health)—A once-daily 15 mg dose of upadacitinib for rheumatoid arthritis (RA) has similar rates of malignancies, serious infections, major adverse cardiovascular events, and venous thromboembolic events as other Janus kinase inhibitors (jakinibs), results from phase 3 clinical trials suggest. Researchers examined data on treatment emergent adverse events among patients taking upadacitinib in five randomized…
The Great Debate: Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?
ACR CONVERGENCE 2020—In many ways, the current plethora of treatment options for rheumatoid arthritis patients represents an embarrassment of riches. However, while many therapeutics approved by the U.S. Food & Drug Administration (FDA) are available, knowing the order in which to try these medications with patients can be quite challenging. In The Great Debate, held…
Conquering Systemic Racism in Medicine
2020 has not only borne witness to a global pandemic, but also to increasing fervor in the fight for racial equity. In a wave of opposition to the systemic racism in the U.S., people have been in the streets demonstrating and protesting against social injustice and have taken to social media to promote political action….
- « Previous Page
- 1
- …
- 44
- 45
- 46
- 47
- 48
- …
- 65
- Next Page »